Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;12(2):234-245.
doi: 10.1007/s11764-017-0662-8. Epub 2017 Nov 20.

Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life

Christine Miaskowski  1 , Judy Mastick  2 , Steven M Paul  2 , Gary Abrams  3 , Steven Cheung  3 , Jennifer Henderson Sabes  3 , Kord M Kober  2 , Mark Schumacher  3 , Yvette P Conley  4 , Kimberly Topp  3 , Betty Smoot  3 , Grace Mausisa  2 , Melissa Mazor  2 , Margaret Wallhagen  2 , Jon D Levine  3
Affiliations

Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life

Christine Miaskowski et al. J Cancer Surviv. 2018 Apr.

Abstract

Purpose: Limited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors' symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions.

Methods: Survivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated.

Results: Of the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05).

Conclusions: Findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX.

Implications for cancer survivors: Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors' hearing ability, functional status, and QOL.

Keywords: Balance; Chemotherapy; Hearing loss; Peripheral neuropathy; Survivor; Tinnitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of neurotoxicities in a sample of adult cancer survivors (n=609).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. doi: 10.2147/CLEP.S47150clep-5-003. - DOI - PMC - PubMed
    1. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, et al. Survivorship: screening for cancer and treatment effects, version 2.2014. J Natl Compr Canc Netw. 2014;12(11):1526–31. 12/11/1526. - PMC - PubMed
    1. Bellman SC. Monitoring chemotherapy-induced hearing loss in children. Eur J Cancer. 1996;32A(7):1185–8. - PubMed
    1. Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–17. doi: 10.1200/JCO.2011.39.1110. - DOI - PMC - PubMed
    1. Freyer DR, Sung L, Reaman GH. Prevention of hearing loss in children receiving cisplatin chemotherapy. J Clin Oncol. 2009;27(2):317–8. doi: 10.1200/JCO.2008.20.1160. - DOI - PubMed

Publication types

MeSH terms